Mankind Pharma licenses acidity drug Vonoprazan from Takeda Pharmaceuticals for commercialization in India.

Mankind Pharma signs non-exclusive patent licensing deal with Takeda Pharmaceuticals to commercialize acidity drug Vonoprazan in India. Vonoprazan, a potassium-competitive acid blocker (P-CAB), treats acid-related disorders such as Gastroesophageal Reflux Disease (GERD). Mankind Pharma aims to address a significant medical need and improve patients' health outcomes with this innovative treatment.

July 16, 2024
3 Articles